Investor Presentaiton

8 Commercial execution and innovation Diabetes care Novo Nordisk progresses towards strategic aspiration of reaching more than 1/3 of the diabetes value market Diabetes care sales Progress made towards Strategic Aspiration DKK billion Value market share 120 6% 4% 4% 8% 13% 80% 100 80 00 60 60 40 40 20 20 0 2017 Injectable GLP-1 Growth at CER 2018 2019 2020 2021 Oral GLP-1 Insulin Other Diabetes care CER: Constant exchange rates; NN: Novo Nordisk; MS: Market share Source: Reported sales per year and sales growth at CER; IQVIA MAT, December 2021 (Spot rate) 60% 49.1% 40% 42.3% 27.5% 20% Novo NordiskⓇ 53.1% 44.0% 30.3% 0% Dec 2017 Dec 2021 NN diabetes MS NN GLP-1 MS NN insulin MS CMD22 CAPITAL MARKETS DAY

View entire presentation